🔗 Share this article

An underground market for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on communication apps, according to new investigations.

Investigational Treatment Gaining Popularity Via Social Media

The experimental drug, which remains in clinical trials, is being advertised by social media influencers for its supposed weight-reducing properties. Viewers are urged to message these accounts privately for source information, while also receiving promotional offers.

Thriving Trade on Messaging Platforms

Separately, a robust trade exists on Telegram, where communities with thousands of members share comparison photos, injection guides and claims of next-day UK delivery. Sellers market the drug there before redirecting customers to other platforms for purchases.

Learning About The Experimental Drug

Retatrutide is an investigational injectable created by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – GLP-1, GIP and glucagon. Preliminary studies indicate it could assist patients lose up to 25% of their total weight. Nicknamed the “triple G”, the drug is being hailed online as the successor to Ozempic.

Healthcare Experts Express Concerns

However, physicians and pharmacists have warned that the sale of what is still an unapproved medication in the UK is a cause for concern and could lead to individuals administering products of uncertain source.

Several experts said the demand for retatrutide could be connected to the rising price of licensed weight loss products such as Mounjaro.

Legal Position and Implementation

Marketing the unapproved drug on TikTok or messaging apps is prohibited in the United Kingdom, as it is an unlicensed drug that cannot be promoted or distributed for human use under the British medical regulations.

Several content creators attempt to circumvent the regulations by referring to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and distribution can still breach medicines, advertising, and customer regulations, potentially leading to fines, legal action or imprisonment.

Service Reaction and Material Elimination

According to the social media company, the platform has removed problematic material and prohibited related keywords and query recommendations. The organization said it was committed to maintaining the platform secure and allocating resources in strengthening compliance measures.

Digital Trading Operations

Investigations also discovered groups with up to nine thousand members marketing the experimental drug using Telegram's built-in discovery tool, which functions like a public directory. Typing “retatrutide” immediately brings up groups with thousands of users, filled with images of weight loss, glowing reviews and detailed instructions for mixing or administering at residence.

Within moments of entering one community, a seller shared contact information, where most purchases take place. The vendor sent an guidebook and guaranteed shipping within two days. When questioned whether the product was genuine, one seller responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one asked about body mass, health issues or previous experience.

Product Information and Pricing

Inside these communities, messages show black plastic packages with Royal Mail stickers, claiming to contain new batches. One communication read: “It took eight of us to load them this morning.”

Customers can choose between dry substance containers, mixed at residence with purified liquid, or ready-to-use pens typically priced at £160 for 20mg. When asked how much time a pen should be used, vendors give contradictory answers varying between a several days to “depends on your body”.

Platform Moderation and Security Actions

A representative for the messaging service stated it regularly monitored dangerous material on its service including material that promoted the “misuse of controlled medications”. The company added that it removed “millions of pieces of harmful content each day”.

Medical Professional Cautions

“People are injecting substances they cannot confirm. Even if the research behind this drug is valid, these digital products may not include what they claim,” said a pharmacy expert, the director of pharmaceutical services at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current price rises for authorized slimming drugs such as Mounjaro. “With costs increasing, patients are turning to online platforms. But counterfeit injections are extremely risky. You can’t be certain what’s inside or whether the conditions they were made in was sterile,” she explained.

Her staff has previously seen patients injured by self-injection from unverified suppliers. “We recognize the disappointment, but buying from Telegram or communication platforms is taking chances with your health,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Producer Statement

A spokesperson from Eli Lilly stated retatrutide was in phase 3 clinical trials and had not been evaluated or authorized by any government authority globally. “Therefore at this time no one can market [it] for personal consumption,” they explained, noting that any product “misleadingly claiming itself as a company experimental product not yet authorized … may expose users to potentially serious health risks”.